| Names | |
|---|---|
| Preferred IUPAC name | 2-[(R)-1-[(R)-2-[(2-chlorophenyl)(phenyl)methoxy]ethyl]pyrrolidin-3-yl]ethyl(dimethyl)ammonium (E)-but-2-enedioate |
| Other names | Tavist Dayhist Clemastinum Meclastin Fumarate de clemastina |
| Pronunciation | /ˈklɛˌmæs.tɪn fjuːˈmæ.rət/ |
| Identifiers | |
| CAS Number | 14976-57-9 |
| Beilstein Reference | 2229790 |
| ChEBI | CHEBI:3698 |
| ChEMBL | CHEMBL1405 |
| ChemSpider | 12167 |
| DrugBank | DB00288 |
| ECHA InfoCard | echa infocard 100.109.008 |
| EC Number | 3.1.1.45 |
| Gmelin Reference | Gmelin Reference: 82145 |
| KEGG | D07735 |
| MeSH | D002968 |
| PubChem CID | 60700 |
| RTECS number | MU4375000 |
| UNII | K0BX1Q6NLM |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C21H26ClNO·C4H4O4 |
| Molar mass | 612.13 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.22 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 3.8 |
| Vapor pressure | Vapor pressure: <1 mm Hg (20°C) |
| Acidity (pKa) | 4.44 |
| Basicity (pKb) | 4.54 |
| Magnetic susceptibility (χ) | -88.6 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.638 |
| Dipole moment | 2.91 D |
| Pharmacology | |
| ATC code | R06AA04 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause drowsiness or dizziness. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | lactose-free, no alcohol, not for pregnant women, not for breastfeeding women, driving warning |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | May cause drowsiness; use caution when driving or operating machinery. Avoid alcohol. Consult your doctor if pregnant, breastfeeding, or taking other medications. Keep out of reach of children. Store at room temperature and protect from moisture. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | 140 °C |
| Lethal dose or concentration | LD₅₀ (oral, rat): 16 mg/kg |
| LD50 (median dose) | LD50 (median dose): 680 mg/kg (oral, rat) |
| NIOSH | SS2975000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 2 mg |
| Related compounds | |
| Related compounds | Diphenhydramine Chlorpheniramine Brompheniramine Triprolidine Promethazine Cyproheptadine Meclizine |
| Parameter | Details & Manufacturer Commentary |
|---|---|
| Product Name & IUPAC Name |
Clemastine Fumarate IUPAC: 2-[(1RS)-1-(2-ethoxyethyl)-1-methylpyrrolidin-3-yl]methylphenyl-dimethylammonium fumarate In production, the name used on labeling and batch documentation depends on region, regulatory listing, and downstream application. Both the common name and IUPAC designation align with pharmacopoeia and import/export documentation requirements. |
| Chemical Formula |
C21H26ClNO·C4H4O4
The chemical formula captures the salt (fumarate) form, not just the Clemastine base. All analytical releases rely on this full molecular description for potency calculations. Monograph compliance and lot-to-lot performance reference the fumarate form due to solubility, bioavailability, and dosage formulation impacts. |
| Synonyms & Trade Names |
Clemastine Hydrogen Fumarate, Clemastinum Fumaricum, Tavist, Meclastin, Clemastine Dimaleate (obsolete in some pharmacopeias)
Naming conventions shift by region and regulatory history. Trade names reflect local market authorizations and finished dosage forms. From a manufacturer view, synonym accuracy is essential in batch release and COA generation to prevent customs compliance issues. |
| HS Code & Customs Classification |
2933.99
Most consignments reference chapter 29 for nitrogenous heterocyclic compounds. Actual subheading (e.g., 29339980) can depend on finished form, mixture content, or local tariff assignment. Misclassification risks shipment delay or regulatory inquiry; frequent updates to local customs guidance must be cross-validated with export documentation. The HS code selection also drives duties, inspection regimes, and supporting paperwork — each lot must match the Bill of Lading HS declaration. |
Clemastine Fumarate is processed and shipped typically as an off-white to pale yellow crystalline powder in final bulk form. Actual color shade can shift slightly between production lots due to trace impurities tied to synthesis conditions and purification yield. Commercial-scale output carries no distinct odor. Melting point observations vary by grade and particle treatment, most reference labs report transitions in the upper 150°C range. Boiling point measurement is not industrially significant, as decomposition occurs well before boiling. Material density is handled in process calculations, mainly for blending and packaging; typical values fall within ranges cited for organic salts of similar molecular structure.
Our experience shows the major stability concern is hydrolysis at elevated humidity and exposure to light, both of which can drive off-spec impurities or breakdown products. Reactivity screening is tailored between salt and base forms, since fumarate introduces its own stability envelope. During formulation, exposure to strong acids, alkalis, or oxidizers is avoided to prevent undesired side reactions or discoloration.
Clemastine Fumarate offers selective solubility: moderate in water and alcohols, lower in non-polar solvents. Solution behavior depends on pH, temperature, and prior micronization. Solution prep for laboratory or industrial use requires gradual wetting to avoid clumping; temperature and agitation protocols often impact yield in process streams. Grade and application determine acceptable solvent types and handling temperatures.
Available grades differ by potency assay, heavy metal content, residual solvents, particle size, and moisture. Pharmaceutical API grades demand tighter limits and analytical purity, with more stringent release standards for endotoxins, microbiological burden, and elemental impurities. Bulk grades for non-pharma end uses may have wider tolerance.
Impurity control depends directly on synthesis efficiency and downstream purification. Known process-related impurities, such as desmethyl derivatives or residual starting materials, are routinely monitored batchwise. Trace-level organic impurities profile reflects route-specific byproduct patterns; acceptable impurity levels align with product grade and region-specific pharmacopeial or customer requirements.
Titrimetric and chromatographic methods dominate final bulk testing. HPLC serves as the reference assay for purity and impurity quantitation. Methods selection follows ICH, local pharmacopeia, or end-user protocol. Test frequency and sample sizes are adjusted for batch scale and criticality of use.
Raw material qualification focuses on main actives and fumaric acid sources. Sourcing philosophy balances consistent supply, documented impurity profiles, and regulatory compliance, especially for pharmaceutical-grade output. Raw material traceability carries through from vendor audit to incoming batch testing.
Industrial synthesis usually builds upon alkylation and subsequent fumarate salt formation. Main route selection pivots around cost, ease of purification, and impurity minimization. The salt formation step is staged to maximize conversion and minimize free base carryover. Route-specific catalysts or phase transfer agents are only adopted when justified by purity or yield improvements.
Critical steps include reaction temperature control, stoichiometry accuracy, and filtration clarity checks. Solvent recovery and impurity rejection via crystallization or activated carbon are common. Filtration, drying, and micronizing steps are batch-specific and adjusted for target particle size distribution as specified by customer or pharmacopeial monographs.
Batchwise release hinges on full analytical verification of identity, assay value, impurity spectrum, and moisture content. For regulated markets, all critical control points are logged and deviation rationales documented. Out-of-spec responses include reprocessing or full waste protocol, never re-blending with new lots.
Modification potential centers on the clemastine base, with key reactions involving N-alkylation or alternative acid salt formation. The fumarate salt reacts under strong acidic or basic hydrolysis, relevant to downstream formulation or stability challenges.
Controlled conditions for main steps involve selection of alcohol or aprotic solvents and moderate temperature to minimize side product formation. Some routes investigate phase transfer catalysis for specific yield improvement, though not universally adopted across all plants.
Potential derivatives result from base modification or salt switching, depending on research or formulation needs. Downstream uses often demand consistency in salt ratio and impurity load to ensure reliable performance in finished medicines or as a reference standard.
Production, warehousing, and transit all mandate tightly closed containers, away from moisture and light sources. Ambient temperature storage is adopted for bulk intermediates, while sensitive applications may require controlled low-humidity and light-impermeable packaging. Specific labelling applies when photostability, hydrolysis, or caking risk is noted in product evaluation.
Primary packaging shifts with grade: pharmaceutical-grade often utilizes HDPE or glass containers with tamper evidence and desiccant. Compatibility tests are part of change-control procedures any time container material changes.
Real-time stability evaluation provides actual shelf life supported by validated test intervals. Degradation usually shows as discoloration and assay drift. Retest practices are applied for non-pharma grades beyond standard expiry periods, with off-spec batches identified before dispatch.
Bulk clemastine fumarate is classified according to the latest GHS criteria for acute toxicity and irritation potential. Labels on final shipping containers follow current regulatory updates for each destination market.
Handling includes warning for possible sensitization, inhalation, or accidental contact risk. Respiratory and eye protection is mandatory in open transfer areas, with local exhaust ventilation installed in granulation, milling, or powder blending zones.
Toxicology is established primarily from animal studies and clinical data. Oral exposure at manufacturing scale is minimized by closed transfer and containment protocols; potential health risks are communicated via site safety induction and batch safety data sheets.
Worker exposure management involves air monitoring (where required), batchwise cleanliness checks, and routine PPE compliance. Exposure guidelines update with evolving regulatory and toxicological reviews, including any new category changes for chronic or reproductive risk.
Production output for Clemastine Fumarate remains governed by installed reactor volume, solvent recovery rate, route yield, and batch-changing frequency. Annual capacity fluctuates according to upstream intermediate supply, plant turnaround schedule, and confirmed contract volume. Output allocation tilts toward large-scale orders, with specialty and reference-standard lots produced only upon confirmed technical agreement. In years where certain raw materials trend volatile (especially key precursors and solvents), scheduled batches are allocated primarily to pre-contracted buyers.
MOQs for Clemastine Fumarate are grade- and customer-spec-dependent. Technical-bulk grade typically starts at drum-scale MOQs; clinical or R&D quantities can be as low as a few hundred grams but incur premium surcharges. Standard lead times usually span 4–8 weeks from final specification confirmation, with possible extension during periods of abnormal raw material or utility constraints, regulatory review, or environmental monitoring windows. Repeat orders often benefit from pre-qualified supply channels, compressing turnaround when stocks permit.
Packaging follows grade-specific and OEB (Occupational Exposure Band) protocol. Technical-grade product typically dispatches in sealed fiber drums with inner PE liners. GMP-compliant lots deploy tamper-evident, inert-lined HDPE containers under qualified cleanroom filling conditions to address cross-contamination risks. Specialty aliquots for reference or analytical use utilize ampoule vials or screw-capped containers. Choice of transport packaging and secondary containment is contract-and-region-specific, depending on route and destination.
Shipping modalities align with product quantity, destination customs requirements, and client-validated carriers. For APAC and US/EU major importers, EXW and FOB terms dominate, emphasizing direct EPL responsibility. CFR/CIF available upon prior risk assessment and proven logistics chain reliability. Standard payment terms secure over irrevocable L/C or staged TT, especially for customized or clinical grades. Temporary storage, demurrage, and re-export risks get addressed in the master supply agreement, not as generic conditions.
Raw material sourcing for Clemastine Fumarate traces back to aromatic and heterocyclic intermediates, with cost composition driven by purity, supplier tier, and seasonal fluctuations. Price shifts often originate from benzyl chloride and fumaric acid volatility, alongside solvent basket changes. When upstream energy prices swing broadly, both direct and indirect costs rise sharply, especially for multi-step syntheses involving controlled substances or temperature-sensitive stages.
Graded pricing reflects not just assay or purity but compliance with ICH, local pharmacopoeia, residual solvent, and heavy metal content. Clinical or API grades command a markedly higher premium than bulk grades due to extended documentation, batch testing, and regulatory monitoring requirements.
Industrial buyers see pronounced pricing tiers, as technical, analytical, and GMP grades require escalating input control, cross-contamination mitigation, and traceability protocols. As packaging shifts from bulk to small-pack/compliance-certified, per-kilogram cost rises due to line segregation and release testing. Buyers requiring full DMF, CEP, or USFDA documentation face additional integration, auditing, and annual renewal costs—all reflected in net-offer structures. Lower-grade supply, used in non-pharma sectors, does not internalize these overheads.
International supply and demand for Clemastine Fumarate fluctuate according to national formulary inclusion, generic product launches, and local substitution policy. Demand concentration remains high in North America, the EU, Japan, and Southeast Asia. API-grade supply has large contributions from India and China; volume buyers in the US/EU actively dual-source to mitigate single-origin risk and regulatory bottlenecks.
US and EU importers maintain strict adherence to traceability and impurity profile consistency, often qualifying multiple suppliers and performing exhaustive batch re-testing. Japanese procurement focuses on narrower impurity thresholds and longer supplier vetting cycles. India pursues competitive pricing, balancing local synthesis with import fill when market shortages strike. Chinese manufacturers occupy much of the global supply base, benefiting from integrated upstream chains but facing cyclical raw material restrictions and tighter local regulation.
Going into 2026, Clemastine Fumarate faces raw material-driven volatility. Feedstock costs, powered by petroleum or coal-derivatives, are susceptible to both global energy geopolitics and regional environmental clampdowns. Macroeconomic factors like logistical gridlocks or regulatory resets further shake spot prices, especially for GMP-compliant lots. Downward price pressure emerges from new capacity ramp-ups and increased regulatory harmonization in India and China, but trade uncertainty and compliance auditing push against margin erosion. Market tracking relies on internal batch-costing, external commodity reports, and regional tender data.
Recent market cycles have seen temporary constraints on key precursor intermediates, notably due to environmental production halts in Eastern China and customs delays affecting outbound shipments. Lead times stretched in periods of heightened anti-pandemic controls.
Several regulatory authorities have either revised impurity thresholds or implemented eCTD filing prerequisites for API registration. Documentation updates, batch archiving protocols, and increased focus on nitrosamine impurities have altered the qualification workload on both the manufacturing and release side. Suitable change control procedures, validation of cleaning protocols, and extended stability data now serve as standard requirements for regulated market shipments.
Continual upgrades in process route yield, investment in closed-system handling, and on-site effluent management assist in buffering raw material unpredictability. Manufacturers invest in automation of routine analysis, redundancy in key intermediates, and strategic safety stock agreements with major buyers. Explanation of any major deviation remains integral to batch release, and proactive regulatory engagement using data-driven justifications anchors long-term supply confidence.
Clemastine fumarate primarily serves pharmaceutical formulation, particularly in antihistamine medications. The main users include prescription and over-the-counter medicine manufacturers, contract manufacturers handling finished dose production, and specialized laboratories involved in generic development. For formulation compatibility, the control of particle size, residual solvents, and trace impurities determines downstream suitability.
| Application | Recommended Grade | Critical Property Focus | Operating Considerations |
|---|---|---|---|
| Oral Solid Dosage Pharmaceuticals | Pharma grade | Purity, particle size, microbiological status | Direct blending, compaction sensitivity, dissolution rate |
| Liquid Formulations | Pharma grade | Solubility, endotoxin control | Base solution clarity, filtration compatibility |
| R&D/Analytical Reference | Reference/Standard grade | Traceability, lot documentation | Method validation, reference spectrum availability |
| Parameter | Oral Solid | Liquid Formulation | Reference Grade |
|---|---|---|---|
| Assay (purity) | Grade-dependent, subject to regulatory minimums | Consistent with pharmacopeia specification | Traceable to certified reference material |
| Impurities | Profiled for relevant regulatory monograph | Low levels required due to solution stability | Documented for reference use |
| Moisture Content | Controlled for production batch flow | Controlled for solution reconstitution | Not typically application-limiting |
| Microbial Load | Monitored during packaging | Monitored for parenteral-grade, rarely requested | Testing available on request |
Determining tablet, syrup, or analytical use guides the starting point for grade type and analytical profile. Production lines configured for direct compression or wet granulation require specific particle characteristics and blending compatibility. Analytical use cases often need additional documentation for traceability.
Local and export market destination dictates the pharmacopoeial references, registration status, and potential batch release controls. US, EU, and select Asian regions follow distinct monograph outlines, which impact tolerable impurity levels and test scope.
Pharmaceutical dosage manufacturing typically demands levels aligned with major pharmacopeias. For route-specific generics, stricter impurity cut-offs may apply, depending on bioequivalence test plans. R&D and analytical requests may emphasize lot-to-lot trace consistency or spectrum documentation.
Production scale influences packaging size and cost control. Batches destined for routine generics often draw from bulk lots, with smaller format packaging prioritized for high-value or sensitive research applications.
Pilot-scale sampling enables formulation and QC labs to confirm direct process compatibility and impurity behavior under established plant or lab conditions. Manufacturing recommends validating initial pilot samples to assess need for further grade tuning.
Primary raw materials trace to established chemical suppliers, typically with dual-source QA for supply continuity. Selection emphasizes precursor purity, reactivity profile, and historical lot variability, reviewed periodically as part of vendor approval.
Production routes hinge on impurity generation patterns and downstream ease of purification. Genotoxic impurity controls guide reagent choice, especially on scaling up to multi-batch campaigns. Manual and automated step-wise controls reduce batch-to-batch deviation.
Critical process controls include stepwise impurity isolation, in-process moisture, and endpoint proteinaceous contaminant removal. Adjustments to temp and solvent ratios rely on statistical process output tracking. Batch consistency reviews focus on both assay values and impurity fingerprint alignment with historical standards.
The process applies stage-specific purification, typically using solvent re-crystallization or phase extraction. In-process controls capture critical points for moisture, particulate presence, and color changes, with rapid in-lab analytics confirming go/no-go decisions.
Final release meets customer or regulatory documentation demand as defined per the targeted grade. Actual test scope covers appearance, assay, impurity content, moisture, and other key attributes. Where end-use is pharma, release criteria integrate pharmacopoeial chapter references plus in-plant sampling data.
Every batch of Clemastine Fumarate relies on robust systems that align with internationally recognized quality management frameworks. Site certifications such as ISO 9001 reflect the ability to execute rigid process control, root cause investigation, and change management. These systems guide how we log and trace every stage from raw material intake, batch formulation, purification, and final product lot coding. The effectiveness of these certifications depends on regular technical system audits, operational discipline on the shop floor, and incident management that involves direct corrective and preventive action tracking.
For pharmaceutical grade Clemastine Fumarate, GMP accreditation applies to every stage—from synthesis routes, selection and identity testing of starting materials, up to batch release by qualified person review. GMP compliance highlights the importance of validated production equipment, process-specific cleaning, segregation between high and low potency compounds, and real-time monitoring. Depending on the regional supply destination, the product can be accompanied by national regulatory registration or site audits by health authorities. The scope and depth of documentation vary, often defined by regional registration status or end application requirements.
A comprehensive documentation package follows each production lot. Standard documentation includes Certificate of Analysis, detailed batch manufacturing records, impurity profiling, and stability data summaries when available. For critical application or regulatory registration, data can be extended to include site master file, cleaning validation summary, equipment and environmental monitoring logs, and supply chain traceability documentation. Some certificates, particularly product-specific impurity studies, may only be applicable to certain grades or release criteria defined by the target pharmacopoeia monograph. Release documentation is batch-linked, and retains the original analytical results as per retention policy.
Clemastine Fumarate production schedules are based on a rolling capacity reservation system, actualized by historical orders and forecast consultation with end users. For stable long-term supply, the production site operates at buffered output levels, supporting both routine orders and demand spikes. Buffer stock arrangements are specific to annual agreement holders, allowing shorter lead times during critical project phases or regulatory review periods. Long-term business plans mean technical support is available during process transfer, analytical method roll-out, or regulatory submission. Flexible supply models include consignment, deferred delivery, or split shipments to distribute inbound risk.
Core synthesis trains are matched to Clemastine Fumarate product lines. The equipment set-up leverages single-use or dedicated reaction vessels when batch cross-contamination must be controlled. The core train selection or redundancy strategy guarantees continuity, even during maintenance shutdowns or increased demand. Lead times and supply frequency adapt to grade-specific downstream requirements; pharmaceutical grade lots require additional hold time for testing and documentation. Stability and resilience depend on redundancy in raw material sourcing, proactive qualification of secondary suppliers, and seasonal production volume mapping.
Technical trial or validation batches are available to qualified formulators or manufacturers. The typical application process requests a technical data summary or project brief to define the sample grade, volume, packaging, and analytical reporting needs. Priority is given to applications involving new dosage form development, registration, or process validation. Each sample shipment is traceable by unique batch code, with accompanied documentation that matches the main production stream. For specialized studies such as impurity or stability assessment, customized sample packaging and extended certificates can be arranged to reflect trial design.
Business models for Clemastine Fumarate adapt to end-user application or project timelines. Spot batch supply, annual call-off contracts, rolling forecast commitments, and milestone-based deliveries are all realized according to negotiated terms. Cooperation plans include regular technical support, analytical method transfer documentation, and access to regulatory change notification. Each cooperation path incorporates the flexibility for adjusting batch quantities, staggered delivery, turnaround for urgent lots, and integrated technical review sessions during early stage formula optimization. The actual model is defined by mutual agreement and forecast stability, with additional customization for joint development or market launch scenarios.
Development teams focus on optimizing synthesis pathways to improve product yield, chemical purity, and process sustainability. Due to clemastine fumarate’s role as an antihistamine, there is heightened interest in reducing manufacturing variance and controlling impurity profiles, especially genotoxic and residual solvent risks. Regulatory expectations drove the adoption of greener solvents and more effective in-process monitoring. Specialized analytical methods, such as HPLC with mass spectrometric detection, are used to characterize batch-to-batch consistency and profile trace substances relevant to final release quality.
While clemastine fumarate’s primary application remains in allergy relief formulations, researchers evaluate its potential in neurological and off-label uses. Development teams observe growing inquiry from compounding pharmacies and innovator companies in CNS-related application research, demanding flexible technical support concerning excipient compatibility, dissolution rate, and stability in non-standard matrices.
Manufacturing challenges revolve around controlling polymorphism, reducing residual organic impurities, and ensuring trace metal compliance. R&D groups prioritize purification strategies to minimize side product carryover and enhance finished batch reproducibility. Continuous improvement in crystallization and washing protocols has reduced risk from moisture-sensitive processing stages. Improvements in real-time monitoring and online control systems have delivered shorter batch cycle times and reductions in human error, leading to better compliance with internal and regulatory release criteria.
Based on customer requests and consultation with both generic and specialty pharma, market demand is expected to show slow but steady growth in established markets, primarily driven by prescription and OTC requirements. Opportunities in emerging regions reflect changing regulations and increased access to pharmaceutical supply. Parallel to this trend, there is a shift toward custom-grade clemastine fumarate, driven by more stringent finished product registration standards and the evolution of pharmacopoeia monographs.
Process teams foresee an industry-wide push toward continuous flow chemistry and further digitalization of sampling and analytical review. These shifts target both regulatory risk reduction and reduced operational footprint. Synthetic chemists invest in continuous process monitoring, computerized batch tracking, and advanced data analytics to manage production deviations and reduce waste. Sourcing logic increasingly considers supply stability for both starting materials and critical purification reagents to meet evolving compliance needs.
Process adjustments focus on solvent recovery, water use minimization, and transition to less hazardous reagents wherever possible. Internal review cycles assess waste generation points, especially in mother liquor disposal and post-reaction treatment, driving incremental changes in raw material selection. Environment and safety committees monitor process byproducts to minimize plant emissions and align with stricter environmental standards, reflecting the global push for lower-energy and lower-carbon production routes.
Direct communication lines between technical staff and customer QA/QC allow for joint review of certificate of analysis, impurity profile, and process route transparency. Support teams routinely provide information on raw material traceability, grade customization, and regulatory documents required for end-market audits. Production-related queries about batch history, deviation investigation, and repeat sampling are answered by experienced process chemists and quality assurance specialists, according to the specificity of the customer’s application.
Technical service chemists assist customers in identifying optimal grade selection for solid, semi-solid, or liquid end-product formulation. Support includes pre-formulation discussions, compatibility studies with customer excipients, and risk assessment for stability or dissolution performance in specific dosage forms. For customers developing modified-release or pediatric applications, teams offer guidance on micronization, granulation method, and potential effects of source variation on dissolution kinetics.
Ongoing batch quality documentation, reanalysis support, and investigation of customer-reported issues form the core of after-sales activity. For customers with specific regulatory, pharmacopoeial, or custom specification requirements, tailored batch release reporting and rapid feedback mechanisms are standard operating procedure. Manufacturing teams maintain ready access to process and batch history records for all deliveries, ensuring any retrospective investigation or support aligns with documented process controls and specification compliance at the time of release.
At our chemical plant, we manufacture Clemastine Fumarate through tightly controlled synthesis and finishing processes formulated in-house. All operations take place within our own facilities, under protocols audited for traceability and repeatability. This approach keeps the material consistent, whether orders run by the kilogram or reach multi-metric-ton, and lets our customers in the pharmaceutical and formulation sectors plan production runs with confidence.
Direct buyers from the pharmaceutical industry deploy Clemastine Fumarate as an active component in antihistamine drug manufacturing. Finished formulations, including oral solutions, tablets, and combination products, all call for this material to meet strict purity and identification criteria. Several veterinary product line manufacturers also rely on Clemastine Fumarate for its antihistaminic properties, especially where consistent supply is critical for year-round SKU availability.
Beyond finished drugs, bulk Clemastine Fumarate supports contract manufacturing organizations and generic drug developers responding to strict project timelines. With regulatory expectations tightening worldwide, the pressure has never been greater to prevent disruptions linked to variation in raw material properties or trace-level contaminants.
We operate our own QC laboratories beside synthesis and packaging halls, where each lot undergoes full release testing against agreed monograph parameters. Instrumental methods, physical analysis, and impurity profiling remain in scope for every delivery. Our protocols do not shift with demand surges or changing regulatory climates; customers always receive material manufactured and released to the same internal specifications.
Pack-out for Clemastine Fumarate runs from small paperboard fiber drums up to palletized bulk containers designed with industrial filling and emptying in mind. Each unit leaves our facility under clear lot identification, sealed for transit, and supported by CofA documentation. Whether buyers need to plug into just-in-time pharmaceutical production or build buffer stocks for quarterly campaigns, we adapt quantities to match business needs.
We back every shipment with technical assistance from formulation troubleshooting to regulatory file support. Our technical managers provide direct answers on specification alignment, analytical method compatibility, and stability documentation. When new projects launch or specifications shift, buyers can consult with our process development and scale-up teams without navigating layers of middlemen or resellers.
Direct procurement gains the advantage of guaranteed source control. We align our production with customer schedules and safety stock needs, supporting contingency planning for major manufacturers and CMOs. Distributors working with high-throughput contract businesses depend on repeatable performance and batch-to-batch supply that meets audit and customer file requirements. Procurement officers address risk by dealing with a single accountable party controlling every stage from raw input to finished goods—the actual producer.
Our priorities remain stable, on-spec production and transparent business exchange, removing uncertainty for partners who require Clemastine Fumarate as a dependable, industrial-grade ingredient.
We manufacture Clemastine Fumarate using refined synthetic processes designed for high purity APIs. As an established antihistamine, Clemastine Fumarate has held a steady spot in allergy therapy, particularly for relief of symptoms associated with allergic rhinitis and urticaria. Our technical staff maintain strict quality oversight during production to ensure every batch meets tight specifications, which is essential given the compound’s mechanism.
Clemastine Fumarate operates as a histamine H1-receptor antagonist. By directly blocking H1 receptors, it cuts off the cascade triggered by histamine release— reducing sneezing, nasal itching, watery eyes, and hives. In practice, the molecule competes with endogenous histamine at the peripheral histamine receptors, stopping transmission of signals responsible for most classic allergy symptoms. Our production team optimizes the crystalline structure to support a reliable dissolution profile, important for rapid onset of action in acute allergenic episodes.
Beyond basic antagonism, Clemastine’s anticholinergic properties can also reduce secretions from mucous membranes, contributing to drier nasal and respiratory passages. Feedback from formulation partners has highlighted the stability and reproducibility of our product’s pharmacokinetic behavior, developed through years of experience scaling synthesis for the pharmaceutical sector.
Approved adult dosing for Clemastine Fumarate most often follows a regimen of 1 mg to 2 mg administered twice per day. The onset of action typically occurs within one hour of oral intake. Doses above 2 mg twice daily may increase the risk of anticholinergic effects—such as drowsiness or dry mouth—without proportional benefit in symptom control. For pediatric applications, medical professionals usually recommend reduced dosages, although specific adjustments depend on age and body weight. Our product is supplied in standard strengths to simplify accurate compounding by pharmaceutical customers.
Our technical documentation covers stability data for oral and parenteral applications. Routine batch analysis confirms that our production maintains both assay and impurity profiles as required by pharmacopeial standards, which supports consistent patient outcomes when dosing guidelines are followed.
Allergic reaction management hinges not only on molecular performance but also on the ability to forecast and deliver high-quality supply. We field inquiries regularly on excipient compatibility and can provide guidance during formulation to ensure Clemastine Fumarate remains bioavailable in solid, liquid, and parenteral dosage forms. Our operations team tracks the lot-to-lot reproducibility with every manufacturing series to minimize deviations that could impact customer confidence.
We recognize that changes in allergy management, such as modified release formulations and the drive for pediatric-friendly dosing, require technical flexibility. Ongoing investment in process optimization allows us to provide extended technical support for partner development teams working on new delivery systems or methods for tailoring dosing regimens based on recent clinical perspectives.
As a manufacturer, we carry a responsibility to support safe use from production line to end application. We maintain all relevant regulatory documentation available for review to help our business partners align with local and international compliance requirements related to Clemastine Fumarate.
As the direct manufacturer of Clemastine Fumarate, we understand that our customers expect consistency and reliability for every order. The material leaves our GMP-compliant plant in packaging specifically developed for pharmaceutical actives. Our standard packaging for Clemastine Fumarate includes fiber drums lined with double polyethylene inner bags, each sealed for stability during transit and long-term storage. The most common sizes we dispatch are 1 kg, 5 kg, and 25 kg net weight per drum. This sizing matches demand patterns in both pilot-scale development and established high-volume production environments. For contract partners and repeat clients, we can accommodate custom weight increments, provided they meet our minimum order requirements and packaging integrity guidelines.
Our choice of industrial-strength fiber drums is not arbitrary. Polyethylene liners keep ambient moisture away from this sensitive compound, reducing hydrolysis risks, while the rigid outer shell safeguards against compression damage. Every closure system undergoes QA inspection before sealing. As a direct producer, we hold full traceability on all lot and batch numbers down to packaging and closure materials, which allows for continuous improvement in container performance and regulatory compliance.
Lead time is a point of pride and a fixed part of our client service philosophy. For orders within our regular product line and specification, Clemastine Fumarate typically ships within three to four weeks from confirmation—assuming no special testing or documentation requirements outside the norm. Our inventory planning and on-site warehousing allow us to keep buffer stocks of key active ingredients, including Clemastine Fumarate, in primary packaging. This investment in safety stock helps us minimize spikes in lead time during periods of unexpected demand.
The real bottleneck, if it occurs, usually stems from custom analytical requests, packaging sizes off our standard drum formats, or unique import documentation. Our team has worked to streamline QA release and regulatory document generation, so requests for pharmacopoeial certificates, technical data sheets, or additional impurity profiles fold into the typical, not the exceptional, workflow. If a customer requires non-standard packaging—for instance, small-sized sampling or full-containment packing for high-potency facilities—we collaborate closely to adapt our line while maintaining chain of custody and GMP traceability.
For urgent supply needs or process changes on the client side, we work directly with procurement and technical representatives to prioritize production slots. Our scheduling team maintains close coordination between compounding, QA, and logistics functions, which puts us in the position to meet expedited timelines with clear communication about feasibility. Clients with blanket agreements or forecasted annual consumption receive priority scheduling, which reduces wait times even further.
Direct manufacturing control matters for every client looking for traceable, cGMP-compliant excipients and APIs. By keeping packaging, warehousing, and shipping in-house, we support uninterrupted supply chains and predictable project execution—something traders or outside distributors cannot guarantee. The reduced risk of mismatched packaging, exposure to environmental fluctuations, and lack of batch-level documentation gives our customers peace of mind during audits and regulatory reviews. Our approach reflects the reality of production-scale pharmaceutical chemistry, not just a brokerage transaction.
Any new project or routine re-order of Clemastine Fumarate receives the same level of attention to packaging quality and lead time transparency. Our decades in chemical production have taught us the importance of direct communication, packaging reliability, and realistic scheduling from the sourcing stage through final delivery.
Producing Clemastine Fumarate at industrial scale means our operations always account for global storage and regulatory needs. With years of hands-on experience in pharmaceutical manufacturing and export compliance, our technical and logistics teams keep a close watch on the controlled handling of this active pharmaceutical ingredient as it moves from our facility to customers worldwide.
Clemastine Fumarate is an antihistamine that calls for careful storage management due to its chemical properties. We keep our material in a tightly sealed container away from light, moisture, and sources of contamination. Industry-standard PVC drums or double-lined fiber drums with polyethylene bags offer optimal protection during warehousing and cross-border shipment. All storage areas at our plant remain well ventilated, and temperatures are kept below 25°C to preserve product integrity throughout its shelf life. During transport, we secure containers on stable pallets to guard against vibration and accidental exposure to direct sunlight or strong heat. These procedures help avoid degradation or unplanned contamination.
International shipment of Clemastine Fumarate does not face the same level of restriction as many controlled substances or listed precursors. Still, agencies in each destination country enforce strict compliance with pharmacopoeial standards and Good Manufacturing Practice. Imports often undergo scrutiny by national drug and customs authorities, who check documentation such as Certificate of Analysis, MSDS, and compliance with local monographs. For example, the import process in the United States follows FDA guidelines, while European clients expect conformity with the European Pharmacopoeia and proper REACH registration. Deliveries to certain Asian and Middle Eastern countries may require additional material safety and origin documentation at customs checkpoints. Our regulatory affairs specialists track any policy changes impacting transit, and we make sure the paperwork always matches the intended application—whether for formulation, repackaging, or research.
Clients in the pharmaceutical industry prefer partners who anticipate and avoid shipping delays or customs rejection. Over the years, our team has built a deep understanding of export and import processes. We help our partners by sharing advance notice of regulatory changes and providing compliance documentation up front. Every shipment comes with detailed labels stating batch number, production date, shelf life, and storage instructions. If our partners have unique handling standards or internal auditing procedures, we can align our packing lists and declarations accordingly.
Sometimes weather disruptions, strikes at ports, or new regulatory rulings challenge previously established procedures. In response, we work directly with shipping partners who understand pharmaceutical requirements and offer climate-controlled transit when needed. Should any unplanned delays or customs reviews arise, our support team provides supporting certificates and technical data without delay, helping clear goods as swiftly as possible.
As a manufacturer with decades in the field, we know that maintaining the quality and legal compliance of Clemastine Fumarate benefits all parties in the distribution chain. By focusing on detailed documentation and professional packaging, we support our partners in navigating unpredictable international requirements. With every consignment, our aim remains the same: product safety, regulatory certainty, and confidence for the end user.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
